Woo Hyun Sun, Lee Kyoung Hwa, Yoon Phill Hoon, Kim Su Ji, Park Inkeun, Kim Young Saing, Ahn Hee Kyung, Hong Junshik, Shin Dong Bok, Sym Sun Jin
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Cancer Res Treat. 2015 Oct;47(4):949-53. doi: 10.4143/crt.2014.052. Epub 2014 Oct 28.
Oxaliplatin is a third-generation platinum derivative used for metastatic or advanced colorectal cancer treatment. Although myelosuppression is the most common cause of oxaliplatin-induced thrombocytopenia, rare cases of oxaliplatin-induced immune-mediated thrombocytopenia are reported. We report a case of a 57-year-old woman with colon cancer who developed gum bleeding and petechiae after oxaliplatin infusion. Laboratory tests revealed grade 4 thrombocytopenia and grade 4 neutropenia. She recovered from the thrombocytopenia and accompanying neutropenia within 4 days with no recurrence following discontinuation of oxaliplatin. Physicians need to be aware of the risk of severe acute thrombocytopenia following oxaliplatin administration.
奥沙利铂是一种用于治疗转移性或晚期结直肠癌的第三代铂类衍生物。虽然骨髓抑制是奥沙利铂诱导血小板减少症最常见的原因，但也有罕见的奥沙利铂诱导的免疫介导性血小板减少症的病例报道。我们报告一例57岁结肠癌女性患者，在输注奥沙利铂后出现牙龈出血和瘀点。实验室检查显示4级血小板减少和4级中性粒细胞减少。停用奥沙利铂后，她在4天内从血小板减少及伴随的中性粒细胞减少中恢复，且未复发。医生需要意识到奥沙利铂给药后发生严重急性血小板减少症的风险。
